SIV Technologies

SIV Technologies is a biotechnology company developing a proprietary platform called Selective Immune Vehicles (SIVs) for the targeted delivery of therapeutic payloads, specifically mRNA, to precise cell populations within the immune system. By utilizing engineered lipid nanoparticles (LNPs) that can home in on specific immune cells in vivo, the company aims to create a new class of precision immunotherapies for cancer, autoimmune disorders, and infectious diseases. This approach seeks to overcome the limitations of current cell therapies by eliminating the need for complex and costly ex vivo cell engineering. The company was founded by world-renowned RNA delivery expert Prof. Dan Peer and is backed by prominent venture capital firms including a16z Bio + Health and OrbiMed. SIV Technologies is currently in the pre-clinical stage, advancing a pipeline of targeted RNA therapies designed to modulate the immune system with high specificity.